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Abstract
Background: Tumor tolerance and immune suppression remain formidable obstacles to the efficacy of immunotherapies
that harness the immune system to eradicate breast cancer. A novel syngeneic mouse model of breast cancer metastasis
was developed in our lab to investigate mechanisms of immune regulation of breast cancer. Comparative analysis of low-
metastatic vs. highly metastatic tumor cells isolated from these mice revealed several important genetic alterations related
to immune control of cancer, including a significant downregulation of cd1d1 in the highly metastatic tumor cells. The cd1d1
gene in mice encodes the MHC class I-like molecule CD1d, which presents glycolipid antigens to a specialized subset of T
cells known as natural killer T (NKT) cells. We hypothesize that breast cancer cells, through downregulation of CD1d and
subsequent evasion of NKT-mediated antitumor immunity, gain increased potential for metastatic tumor progression.
Methodology/Principal Findings: In this study, we demonstrate in a mouse model of breast cancer metastasis that tumor
downregulation of CD1d inhibits iNKT-mediated antitumor immunity and promotes metastatic breast cancer progression in
a CD1d-dependent manner in vitro and in vivo. Using NKT-deficient transgenic mouse models, we demonstrate important
differences between type I and type II NKT cells in their ability to regulate antitumor immunity of CD1d-expressing breast
tumors.
Conclusions/Significance: The results of this study emphasize the importance of determining the CD1d expression status of
the tumor when tailoring NKT-based immunotherapies for the prevention and treatment of metastatic breast cancer.
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Introduction
Significant progress has been made over the past few decades in
developing breast cancer immunotherapies that inhibit tumor
progression and prevent metastasis [1]. While recent advances
in tumor vaccines and T cell-based immunotherapies appear
promising, tumor tolerance and immune suppression remain
formidable obstacles to eradicating breast cancer [2]. It is widely
believed in the field of metastasis that tumor cells must acquire
multiple genetic alterations to enable colonization in distant organ
sites [3]. Of these, evasion of host immune surveillance is an early
and critical step. Cancer cells, like bacteria and viruses, are known
to evolve a number of strategies to escape immune surveillance
[4,5]. For example, cancer cells have been documented to
downregulate or alter MHC class I molecules and their
presentation of tumor antigens to escape immune surveillance, a
process known as immunoediting [6,7]. Identifying critical genetic
alterations that enable immune evasion and tumor tolerance will
facilitate the development of immunotherapies that eliminate
breast cancer.
In order to identify potential gene signatures for metastasis using
our syngeneic mouse model of breast cancer metastasis, we
compared low-metastatic TM40D breast cancer cells with the
highly metastatic TM40D-MB cells by microarray [8]. This
revealed a number of immune response genes altered between
these cells that were not identified in previous arrays using
immune deficient xenograft mouse models [9]. Of these, a
significant downregulation was found in the TM40D-MB cells of
the cd1d1 gene, encoding the MHC class I-like molecule CD1d.
CD1d molecules present glycolipid antigens to a specialized class
of immune cells known as natural killer T (NKT) cells [10]. NKT
cells can be divided into two main types: Type I NKT cells, or
invariant NKT (iNKT) cells, are characterized by an invariant
TCRa chain consisting of Va14Ja18 gene segments in mice
(Va24Ja18 in humans) and can promote either Th1 or Th2
effector responses, depending on their activation [11,12]. Type II
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a diverse TCR repertoire, and have mainly immune regulatory
functions [13]. In cancer, accumulated evidence points to a
protective role for type I (iNKT) cells, whereas type II NKT cells
have been shown to be mainly immunosuppressive [14].
Clinically, iNKT levels are significantly reduced in solid tumors,
and low levels of circulating iNKT cells correlate with a poor
prognosis in many types of cancers, including breast cancer
[15,16,17,18].
Multiple preclinical and clinical studies support the notion that
inducing iNKT cell activation can inhibit tumor progression and
promote lasting tumor immunity [19,20]. Activated iNKT cells
can rapidly produce pro-inflammatory cytokines such as IFN-c,
which activates innate natural killer (NK) effector function and
induces maturation of dendritic (DC) cells that produce immune-
stimulating IL-12 [21]. This leads to activation of secondary
immune effector responses, including maturation of CD8
+ T cells
to antigen-specific antitumor cytotoxic T lymphocytes (CTL)
[22,23]. In addition to their role in activating antitumor NK and T
effector function, iNKT cells can induce direct cytolysis of tumor
cells [24]. Activated iNKT cells have been demonstrated to be
directly cytotoxic to CD1d-bearing tumor cells in a CD1d-
dependent manner in vitro, and studies have directly correlated
tumor expression of CD1d to their sensitivity to iNKT-mediated
antitumor immunity in vivo [25,26].
CD1d is widely expressed in humans and animals in both
hematopoietic and non-hematopoietic cells, including multiple
tumor types [27,28]. CD1d downregulation by human papillo-
mavirus (HPV) in infected cervical epithelial cells has been
recently shown to be correlated with their progression to cervical
carcinoma [29]. Downregulation of CD1d in highly metastatic
breast cancer cells may similarly enable evasion of immune
surveillance and facilitate metastatic progression. To date, no
study has directly linked CD1d expression by breast cancer cells
and iNKT-mediated antitumor immunity in preventing breast
cancer metastasis.
In this study, we provide the first evidence that in human breast
cancer cells, downregulation of CD1d expression is correlated with
increasing metastatic potential. Using our syngeneic mouse model
of breast cancer metastasis, we show that tumor cells expressing
CD1d promote increased iNKT-mediated antitumor immunity in
a CD1d-dependent manner in vitro and in vivo. Importantly,
inhibition of tumor CD1d expression in vivo, by either antibody
blockade or gene silencing, promotes spontaneous breast cancer
metastasis. Interestingly, by comparing tumor growth of CD1d-
expressing and CD1d-deficient tumor cells in NKT-deficient
transgenic knockout (KO) models, we have uncovered important
differences in the regulation of these cells by type I and type II
NKT cells. These results demonstrate a previously unrecognized
role for CD1d-restricted NKT cells in regulating breast cancer
metastasis. In addition, these results point to the CD1d expression
status of the tumor as being an important determinant in tailoring
NKT-based immunotherapies for the prevention and treatment of
metastatic breast cancer. Our findings further support research
into designing breast cancer immunotherapies that bolster the
activation of type I NKT cells, while inhibiting the suppressive
functions of type II NKT cells.
Materials and Methods
Mice
Inbred BALB/c mice were purchased from Harlan Sprague
Dawley Inc. BALB/c mice homozygous deficient in the cd1d1 gene
(CD1d KO) were purchased from the Jackson Laboratory [30].
Recombinase-activating gene 2-deficient (RAG2 KO) BALB/c
mice were purchased from Taconic Laboratories [31]. Ja18 KO
(iNKT deficient) on the BALB/c background (at least 8 gen-
erations backcrossed by Ram Singh, UCLA) mice were provided
by Dr. Randy R. Brutkiewicz (Indiana University School of
Medicine, Indianapolis, IN) [32]. All mice were housed in a
pathogen-free environment at the Northwestern Center for
Comparative Medicine (CCM) facility. All experiments were done
in accordance with protocols approved by the CCM Committee
on Animal Care (CAR) institutional IACUC and in accordance
with AAALAC. Female mice approximately 8 weeks old were used
for all experiments.
Breast cancer cell lines
TM40D mammary tumor cells were derived from the FSK4
mammary epithelial cell line established in vitro from normal mouse
mammary gland [33]. TM40D-MB tumor cells were isolated from
bone by antibiotic selection after intracardiac injection of TM40D
cells, according to a modified method by Li et al [34]. TM40D
tumors have a low potential for spontaneous lung and bone
metastasis after orthotopic mammary gland implantation (7.7%),
whereas TM40D-MB tumors are metastatic to lung and highly
bone metastatic (53.3%) [8]. The TM40D-shCD1d cell line was
created by stable lentiviral knockdown of TM40D cells with a short
hairpin RNA (shRNA) sequence against murine cd1d1 (pLKO.1
vector, clone ID 67863, OpenBiosystems). A scrambled shRNA was
also used as a control (TM40D-scr). All cells were grown in
DMEM/F12 supplemented with L-glutamine, 50 mg/ml strepto-
mycin, 50 U/ml penicillin and 5% heat-inactivated Fetal Bovine
Serum (FBS) (all Invitrogen Gibco BRL). All cells were used within
two weeks of culture (passages 4–6).
In vivo orthotopic mouse model of breast cancer
metastasis
For all tumor experiments, mice were injected bilaterally into
the 4
th mammary fat pads with 1610
6 tumor cells. Tumor volume
measurements were taken every three days, and tumor volume was
calculated using the formula: length 6width
2/2 [35]. Mice were
euthanized at the point at which tumors reached the maximum
allowable size of 2 cm, following AAALAC guidelines and the
rules set by the IACUC. In order to detect spontaneous lung
metastasis, tissues were fixed with Bouin’s fixative for 24 hrs, then
replaced with 70% EtOH [36]. After 48 hrs, tissues were
visualized and photographed under a dissecting light microscope
with attached camera (Olympus SZX12, Olympus America Inc).
For the in vivo anti-CD1d blocking antibody study, 10 mice were
implanted with 1610
6 tumor cells. At the point tumors were
palpable (day 10 post-implantation), 5 mice per group were
administered 200 mg i.p. of anti-CD1d (3C11) blocking antibody
or vehicle (hybridoma supernatant) control [37]. These injections
were repeated at days 17, 24 and 31 post-tumor implantation, and
tumor measurements were taken every three days. At day 45, all
mice had reached the maximum allowable tumor size and were
subsequently euthanized.
Real-time reverse transcription-polymerase chain
reaction (RT-PCR) assay
To validate the microarray results, RNA was harvested from
tumor cell lines (Rneasy kit, Qiagen) and RT-PCR was performed
on reverse-transcribed cDNA (Roche) using primers for the murine
cd1d1 gene, and L19 amplification was used as a control for relative
levels of total RNA, as previously described [38]. For real-time
RT-PCR experiments, the SYBR Green assay (Applied Biosystems)
NKT-Mediated Antitumor Immunity in Breast Cancer
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DNA samples on a real-time cycler (ABI7900HT, Applied
Biosystems).Reactionsforeach samplewere performedintriplicate,
and amplified products were visualized on an agarose gel. The level
of target gene expression was normalized against glyceraldehyde
3-phosphate dehydrogenase (GAPDH) expression in each sample.
For RT-PCR of the human CD1D transcript, the following cell
lines were used: 71N, 81N – normal human mammary epithelial
cells, 21PT, ZR-75-1 – non-invasive primary tumor, MCF-7 –
minimally invasive primary tumor, MDA-MB-468, MDA-MB-231
– pleural effusion, highly metastatic [39,40]. RNA was harvested
(Trizol, Sigma) and reverse-transcribed to make cDNA (Superscript
II,Invitrogen).The followingprimerswereused toamplifya275 bp
fragment from the human CD1D gene: 59-CGC GCA GCG GCG
CTC CGC G-39 located in exon 1, and 59-GGA CCA AGG CTT
CAG AGA G-39 located in exon 2. Primers for human GAPDH
were used as described previously [41].
Fluorescence-activated cell sorting (FACS) analysis
At maximum tumor size, spleen and tumor were excised and
homogenized to obtain single cell suspensions, and erythrocytes
were removed as described [42]. To test for immune cell
recruitment in spleen and tumor, 2610
6 cells from each sample
were preincubated with anti-CD16/CD42 (2.4G2, eBioscience) to
avoid non-specific binding of antibodies to FccR [43]. Cells were
stained with the following fluorophore-conjugated anti-mouse
monoclonal antibodies: anti-CD1d (1B1), anti-TCRb, anti-CD49b
(DX5), anti-CD4, anti-CD8a, anti-CD69, anti-CD45R (all BD
Biosciences), and CD1d tetramers loaded with the aGalCer analog
PBS-57 (NIH Tetramer Core Facility, Atlanta GA). The
percentage of live cells was assessed using the LIVE/DEAD
fixable violet blue cell kit (Invitrogen). Cells were sorted using a
FACS Canto II (BD Biosciences) and analyzed on FlowJo software
(Tree Star).
Enrichment of iNKT cells and in vitro cytotoxicity assay
iNKT cells were enriched from splenocytes of healthy, unchal-
lenged 7 week-old wildtype BALB/c by positive selection as
previously described [42]. Dead cells were removed from
splenocytes using a Dead Cell Removal Kit (MACS, Miltenyi
Biotec).To debulksplenocytes ofB cells,splenocyteswereincubated
with biotin-B220 (BD Biosciences), followed by streptavidin
microbead magnetic column depletion (MACS, Miltenyi Biotec).
For positive selection of iNKT cells, splenocytes were incubated
with a PE-conjugated PBS-57-loaded CD1d tetramer, followed by
anti-PE magnetic column purification (MACS, Miltenyi Biotec).
Percent enrichment and activation status (CD69
+) of iNKT cells
isolated from splenocytes was confirmed by FACS. Activated
iNKT-enriched splenocyteswereimmediatelyincubatedwithtarget
tumor cells at effector to target (E:T) ratios of 5:1, 10:1 and 25:1, in
the presence or absence of anti-CD1d (3C11, BD Biosciences), or
IgM isotype control (Sigma) [44]. After 4 hr incubation at 37uC and
5% CO2, cell-free supernatants were harvested and assayed for
lactate dehydrogenase(LDH)activityasameasureofcelllysis(LDH
Cytotoxicity Detection Kit, Roche) [45]. Spontaneous release of
LDH by effector and target cells were controlled by separate
incubations of these populations. The results were calculated as
follows:
% Cytotoxicity = test release – non-specific release x 100
total LDH release – non-specific release
Statistical analysis
Results are expressed as the median and range and mean 6
standard deviation. Student’s paired t tests or one-way ANOVA
were used to determine statistical significance. A value of P,0.05
was considered statistically significant. Data were analyzed using
Excel for Mac 2008 (Microsoft) and Prism 5 (GraphPad).
Results
CD1d expression is correlated with increasing metastatic
potential in murine and human breast cancer cells
Several lines of evidence support the idea that a small
population of primary tumor cells possess existing molecular
signatures for metastasis [46,47]. In order to identify potential
metastatic signatures using our mouse model of breast cancer
metastasis, TM40D breast cancer cells of low metastatic potential
were compared to the highly metastatic TM40D-MB cells by
microarray [8]. Among the genes that were found differentially
expressed between these two cell lines, we found a 4.72-fold
downregulation of the cd1d1 gene in the TM40D-MB cells. (Figure
S1). This expression difference was validated by real-time RT-
PCR, comparing amplified cDNA for the murine cd1d1 gene by
RT-PCR between the TM40D and TM40D-MB cells (Fig. 1A).
Downregulation of surface CD1d expression in the TM40D-MB
cells was also confirmed by fluorescence-activated cell sorting
(FACS) (Fig. 1B). CD1d is known to be expressed in human breast
tissue, in both ductal epithelial and vascular smooth muscle cells
[48]. Downregulated CD1d expression has been correlated with
decreased iNKT-mediated antitumor immunity in several human
and murine hematopoietic malignancies [24,25,49]. In human
solid tumors, a correlation of downregulated CD1d expression
with increasing malignancy has been reported in malignant
glioma, and most recently HPV-transformed cervical carcinoma
cells [29,50]. In order to assess the importance of CD1d
downregulation in human breast cancer, we analyzed a panel of
human mammary epithelial cell lines of increasing metastatic
potential by RT-PCR for their expression of CD1d (Fig. 1C).
CD1d was found to be expressed in normal human mammary
epithelial cells, and with the exception of MDA-MB-468, is
downregulated in the transition from normal to malignant breast
cancer. These results suggest that downregulation of CD1d
expression in both murine and human breast cancer may be an
important mechanism for evading tumor immune surveillance and
promoting metastatic cancer progression.
CD1d-expressing tumor cells promote direct iNKT-
mediated cytotoxicity in a CD1d-dependent manner in
vitro
Previous studies in hematopoietic tumors demonstrated the
ability of CD1d-expressing tumors to be susceptible to direct iNKT-
mediated cytolysis in a CD1d-dependent manner [25,26,51].
However, the ability of iNKT cells to induce direct cytolysis of
CD1d-expressing breast cancer cells has not been reported. For this
experiment, activated iNKT effector cells were enriched from
splenocytes by positive selection using a ligand-conjugated CD1d
tetramer [42] (Fig. 2A). Activation of iNKT cells by tetramer
ligation was positively confirmed by increased expression of CD69,
a marker for iNKT activation [52]. Enriched iNKT cells were
immediately incubated with either TM40D (CD1d-hi) or TM40D-
MB (CD1d-lo) tumor target cells and assayed for tumor cytolysis.
TM40D (CD1d-hi) tumor cells demonstrated increased cytotoxicity
over TM40D-MB (CD1d-lo) tumor cells in a range of effector to
target cell ratios, and significantly higher cytotoxicity at an E:Tratio
of 25:1 (P,0.05), as measured by the release of lactate
dehydrogenase (LDH) (Fig. 2B). This suggests that enriched iNKT
cells may preferentially target tumor cells expressing higher levels of
CD1d, and downregulation of CD1d may be a mechanism for
NKT-Mediated Antitumor Immunity in Breast Cancer
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that direct iNKT cytolysis of TM40D (CD1d-hi) cells could be
partially blocked by the addition of an anti-CD1dblockingantibody
(3C11)ina range ofeffector to targetcell ratios(Fig. 2C). The ability
of the anti-CD1d antibody to block tumor cytolysis was concentra-
tion-dependent, as compared to isotype control (Fig. 2D). These
results are consistent with previous reports demonstrating suscep-
tibility of CD1d-expressing hematopoietic tumor cells to direct
iNKT-mediated cytolysis, and the ability of anti-CD1d blocking
antibody to partially abrogate this effect [26,51]. To our knowledge,
this is the first study to demonstrate the ability of enriched iNKT
cells to induce direct cytolysis of CD1d-expressing breast cancer
cells in a CD1d-dependent manner in vitro.
Downregulation of CD1d by tumor correlates with
evidence of decreased iNKT-mediated antitumor
immunity in vivo
The ability of CD1d-restricted iNKT cells to promote
antitumor immune responses has been documented in multiple
human and animal cancer studies [14,19,20]. Several studies
have demonstrated a direct role for CD1d-expressing tumor cells
in activating iNKT-mediated antitumor immunity [24,25].
Activated iNKT cells have been shown to prime innate NK
immune responses, as well as activate secondary immune effector
antitumor CD4
+ and CD8
+ T cells [22,23]. We hypothesize that
downregulation of CD1d in breast cancer cells may inhibit
iNKT-regulated primary and secondary immune responses. In
order to assess the effects of tumor downregulation of CD1d on
iNKT-mediated antitumor immunity in vivo, we utilized our
mouse model of breast cancer metastasis to compare the immune
responses of mice implanted with either low metastatic TM40D
(CD1d-hi) cells, or highly metastatic TM40D-MB (CD1d-lo) cells.
For this experiment, TM40D or TM40D-MB cells were
implanted into wildtype BALB/c and monitored for tumor
progression. TM40D-MB tumor cells with downregulated CD1d
expression were found to grow at a slower rate than TM40D
(CD1d-hi) tumors, suggesting that downregulated CD1d expres-
sion may not affect tumor proliferation directly (Fig. 3A). In order
to assess potential effects of downregulated CD1d expression by
tumor on innate and adaptive antitumor immunity, we assessed
spleens from tumor-implanted mice for levels of iNKT, NK,
Figure 1. Decreased expression of CD1d in highly metastatic murine and human breast cancer cells. (A) Real-time RT-PCR assay
confirming significant downregulation of the CD1d1 gene in TM40D-MB cells, as compared to parental TM40D (low metastatic) cells. L19 serves as an
internal control. Experiments were performed in triplicate, and data are represented as the mean 6 SEM, * P#0.05. (B) Flow cytometry analysis of
CD1d using a PE-conjugated anti-CD1d mAb (1B1) or isotype IgG2b control. Average 6 SD mean fluorescence intensity (MFI) for three independent
experiments: TM40D (blue) =928.7621.2, TM40D-MB (red) =541.0657, ** P#0.001. (C) Decreased expression of CD1d in human mammary epithelial
cells correlates with increasing metastatic potential by RT-PCR. 71N, 81N: normal transformed human mammary epithelial cells. 21PT, ZR75: primary
breast adenocarcinoma cells. MCF-7: minimally invasive adenocarcinoma cells. MDA-MB-468, MDA-MB-231: highly metastatic human breast
adenocarcinoma cells, from patients of African-American (MDA-MB-468) and Caucasian (MDA-MB-231) descent. GAPDH serves as an internal
housekeeping gene control.
doi:10.1371/journal.pone.0020702.g001
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+ and CD8
+ T cells by FACS. As a control, these cell
populations were compared to spleen from healthy (unchal-
lenged) mice. Splenocytes isolated from the TM40D (CD1d-hi)
group demonstrated lower levels of NK and iNKT cells as
compared to healthy unchallenged mice, as expected from
immune suppression at this late stage of tumor progression
(Fig. 3B,C). Importantly, splenic levels of NK and iNKT cells of
the TM40D mice were significantly higher than in the TM40D-
MB (CD1d-lo) group (NK and iNKT P,0.001), although tumor
sizes were comparable at time of analysis. This suggests that
downregulation of tumor CD1d expression may have an effect on
NK and iNKT antitumor immunity, even at a late stage in tumor
progression. Both the TM40D and TM40D-MB tumor groups
had decreased splenic levels of CD4
+ and CD8
+ Tc e l l
populations as compared to unchallenged mice, although the
reduction in the TM40D-MB group was significantly more
pronounced (CD4
+ P=0.003, CD8
+ P=0.012) (Fig. 3B,D).
These results suggest that secondary T cell-mediated adaptive
antitumor immunity may also be compromised by downregulated
CD1d expression. In summary, these data point to a correlation
between downregulated CD1d expression by tumor and sup-
pression of iNKT-regulated antitumor immunity in vivo.
In vivo antibody blockade of CD1d in mice bearing CD1d-
expressing tumors promotes spontaneous breast cancer
metastasis
Previous studies have demonstrated the ability of in vivo anti-
CD1d antibody blockade to inhibit tumor progression of CD1d-
deficient tumors [37,53,54]. However, the efficacy of this
Figure 2. Increased tumor cytolysis of CD1d-expressing cells by enriched iNKT cells. (A) FACS analysis of enriched iNKT cells by magnetic
bead sorting using PE-conjugated PBS-57-loaded CD1d tetramer and FITC-conjugated anti-TCRb Ab. Activation assessed using PerCP-conjugated
anti-CD69 Ab. Mean fluorescence intensity (MFI) for control naı ¨ve CD4
+ T Cell=99 (black), Unenriched iNKT=121 (blue), Enriched iNKT=715 (red). (B)
In vitro Lactate Dehydrogenase (LDH) cytotoxicity assay. Positively-enriched iNKT effector cells (.20% iNKT+) were incubated with TM40D or TM40D-
MB target cells at E:T ratios of 5:1, 10:1 and 25:1, for 4 hrs at 37uC, 5% CO2. Cell-free supernatants were assayed for LDH activity as a measure of cell
lysis. (C) TM40D target cells were incubated with enriched iNKT cells at E:T ratios of 5:1, 10:1 and 25:1, in the presence or absence of anti-CD1d (3C11)
blocking antibody (10 mg/ml). (D) In vitro anti-CD1d antibody titration in TM40D cells. Positively-enriched iNKT effector cells (.20% iNKT
+) were
incubated with TM40D target cells at an E:T ratio of 25:1, in the presence of anti-CD1d (3C11) blocking antibody or IgM isotype control, at the
concentrations indicated. Data are presented as mean 6 SD, * P,0.05. Data are representative of at least two independent experiments.
doi:10.1371/journal.pone.0020702.g002
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been verified. Based on our in vitro findings, we hypothesized that
in vivo blockade of CD1d using an anti-CD1d blocking antibody
would inhibit iNKT-mediated antitumor immunity and result in
increased breast cancer metastasis. To test this, wildtype BALB/c
mice were implanted with 1610
6 TM40D tumor cells. At the
point at which tumors were palpable (day 10 post tumor
implantation), mice were injected intraperitoneally (i.p) with either
anti-CD1d (3C11) blocking antibody, or vehicle control [37].
Unlike the anti-CD1d (1B1) blocking antibody used by the
Smyth group, anti-CD1d (3C11) is a non-depleting blocking
antibody that is not known to activate antitumor APCs [55].
Antibody injections were repeated weekly, and mice were
euthanized at maximum tumor volume. Unlike previous studies
using antibody blockade of CD1d-deficient tumors, treatment of
CD1d-expressing TM40D cells with anti-CD1d blocking antibody
did not inhibit tumor growth (Fig. 4A). In order to assess the effect
of CD1d antibody blocking on tumor metastasis, we evaluated
whether anti-CD1d antibody blockade could increase tumor
metastasis to lung. Previous studies in our lab demonstrated that
TM40D tumors have a low rate of spontaneous metastasis [35]. As
assessed by histology, tumors in mice treated with the anti-CD1d
antibody exhibited increased ability to metastasize to lung, with
significantly increased numbers of tumor foci per lung (P=0.0049)
(Fig. 4B,C). Thus, unlike other CD1d-deficient tumors, treatment
of CD1d-expressing breast tumors with an anti-CD1d blocking
Figure 3. Decreased CD1d expression by tumor correlates with decreased iNKT-mediated antitumor immunity in vivo. (A) Orthotopic
injection into the bilateral mammary fat pads of mice with either 1610
6 CD1d-expressing TM40D or CD1d-deficient TM40D-MB cells, 5 mice per
tumor group. Mice were monitored for tumor formation (tumor size of 0.3 cm), and mice in each tumor group were euthanized at maximum tumor
size (2 cm). (B) FACS analysis comparing spleens isolated from either TM40D or TM40D-MB tumor-implanted mice. Splenocytes were isolated from
mice at maximum tumor size and analyzed by FACS for live iNKT cell populations using APC-conjugated PBS-57-loaded CD1d tetramer and FITC-
conjugated anti-TCRb antibodies. Live NK populations were assessed using PE-conjugated anti-CD49b (DX5) and FITC-conjugated anti-TCRb
antibodies. Live CD4
+ and CD8
+ T cell populations were assessed using APC-conjugated anti-CD4 and PerCP-Cy5.5-conjugated anti-CD8a antibodies.
C,(D) Histograms quantifying the total percentage of live iNKT, NK, CD4
+ and CD8
+ T cell of total splenocytes. N=3 (Unchallenged). N=5 (TM40D,
TM40D-MB). Data are mean 6 SD. * P#0.05, ** P#0.001. These results are representative of at least two independent experiments.
doi:10.1371/journal.pone.0020702.g003
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vivo, demonstrating the importance of CD1d expression for iNKT-
mediated antitumor immunity.
Knockdown of CD1d gene expression in TM40D cells
promotes increased breast cancer metastasis
Next we sought to determine the role of tumor-specific CD1d
downregulation, in contrast to systemic CD1d inhibition by
antibody blockade, in promoting spontaneous breast cancer
metastasis. For this experiment, we employed lentiviral delivery
of shRNA against murine CD1d (TM40D-shCD1d). Knockdown
of CD1d expression level in TM40D cells was verified by real-time
RT-PCR, which demonstrated CD1d expression levels in
TM40D-shCD1d cells to be downregulated to a level comparable
to TM40D-MB (Fig. 5A). FACS analysis of TM40D-shCD1d
surface expression of CD1d demonstrated a similar decrease, as
compared to TM40D and TM40D-MB cells (Fig. 5B). When
TM40D-shCD1d cells were implanted into BALB/c mice,
primary tumor growth rates were found to be identical to the
parental TM40D-implanted mice (data not shown). Importantly,
when spleens were harvested from these mice and assessed for
levels of iNKT-mediated immune populations, TM40D-shCD1d
mice demonstrated significantly decreased splenic levels of CD4
+
and CD8
+ T cells (CD4
+ P=0.017, CD8
+ P=0.034), as well as
significantly decreased iNKT cells (P=0.003), as compared to
parental TM40D-implanted mice (Fig. 5C). NK levels were not
significantly affected (data not shown). This supports the notion
that downregulation of tumor CD1d expression may play a role in
suppressing the antitumor immune functions of iNKT cells. In
addition, we analyzed these groups for evidence of lung metastasis,
and found a significantly increased rate and frequency of lung foci
per lung in the TM40D-shCD1d (P=0.0152) mice, as compared
to parental TM40D-implanted mice (Fig. 5D). These results
demonstrate the importance of tumor-specific CD1d expression
for inhibiting metastatic breast cancer progression, and point to
the importance of iNKT-mediated antitumor immunity in
regulating these tumors.
Figure 4. Antibody blocking of CD1d-expressing TM40D tumor cells increases spontaneous lung metastasis in vivo. (A) Comparison of
tumor growth in mice administered anti-CD1d blocking antibody or vehicle control. Wild-type BALB/c mice (5 mice per group) were implanted with
TM40D tumor cells and inoculated I.P. with either with 200 mg of anti-CD1d (3C11) blocking antibody or vehicle control (TM40D-C) at days 10, 17, 24,
and 31 post tumor implantation. Mice were monitored for tumor formation (tumor size of 0.3 cm), and mice were euthanized at maximum tumor size
(2 cm). (B) In vivo anti-CD1d antibody blockade of CD1d-expressing TM40D tumors increases the frequency of lung tumor metastases in mice. At
maximum tumor volume, lung tissues were isolated and fixed in Bouin’s Fixative and scored for visible metastasis foci under dissecting light
microscope. (C) Scatter plot depicting average number of tumor foci counted per lung (** P,0.005, one-way ANOVA test).
doi:10.1371/journal.pone.0020702.g004
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immunity and promotes increased spontaneous metastasis to lung. (A) TM40D cells were transduced by a pLKO.1 lentivirus expressing
shRNA against murine cd1d1. Real-time RT-PCR assay confirming downregulation of the cd1d gene in the TM40D-shCD1d cells, as compared to
parental TM40D and TM40D-MB cells and scrambled shRNA control (TM40D-scr). TM40D-MB cells, as compared to parental TM40D (low metastatic)
cells. GAPDH serves as an internal control. (B) FACS analysis of gene knockdown of CD1d using a PE-conjugated anti-CD1d mAb (1B1) or isotype
IgG2b control. Mean fluorescence intensity (MFI) for IgG2b Isotype Control (black) =127, TM40D-shCD1d (green) =389, TM40D-MB (red) =599,
TM40D (blue) =932. (C) Suppression of iNKT-regulated lymphocytes in vivo of TM40D-shCD1d tumor-implanted mice, as compared to parental
TM40D control. Histograms quantifying the total percentage of live iNKT, and CD4
+ and CD8
+ T cell of total splenocytes. N=5 (TM40D, TM40D-
shCD1d). Data are mean 6 SD. * P#0.05. (D) Scatter plot depicting increased number of tumor foci counted per lung in TM40D-shCD1d tumor-
implanted mice as compared to TM40D parental control. (* P#0.05, one-way ANOVA test).
doi:10.1371/journal.pone.0020702.g005
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CD1d-hi vs. CD1d-lo tumors by CD1d-restricted NKT cells
Recent studies have begun to elucidate a novel immunoregu-
latory axis of CD1d-restricted NKT cells, with type I invariant
NKT (iNKT) having antitumor functions, and type II variant
NKT cells demonstrating mainly immunosuppressive tumor-
promoting abilities [14]. The role of CD1d-restricted type I vs.
type II NKT cells in breast cancer has only been addressed using
the CD1d-deficient 4T1 mammary carcinoma model [37]. The
ability of CD1d-restricted NKT cells to regulate tumor growth and
metastasis of CD1d-expressing breast tumors has yet to be
explored. To address this, we compared tumor growth and
metastasis rates of TM40D (CD1d-hi) or TM40D-MB (CD1d-lo)
cells implanted in wildtype mice, CD1d KO mice that are
deficient in all CD1d-restricted NKT cells, and Ja18 KO mice
that are deficient in only type I NKT (iNKT) cells [30,32].
Additionally, we sought to determine the importance of adaptive
immunity in regulating tumor growth and immune responses
between these tumors using recombinase-activating gene 2
deficient (RAG2 KO) mice, lacking all B and T lymphocytes,
including NKT cells [31].
For these experiments, we first compared rates of tumor growth
and metastasis of TM40D (CD1d-hi) cells implanted in wildtype,
CD1d KO, Ja18 KO and RAG2 KO mice. Tumor growth rates
were found to be similar between wildtype and immune-deficient
mouse groups (Fig. 6A). These results are in line with previous
observations in the CD1d-deficient 4T1 breast cancer mouse
model [37]. In contrast to rates of tumor growth, significant
differences were found between these mouse groups in their ability
to spontaneously metastasize to lung (Fig. 6B,D). TM40D cells
were most metastatic in RAG2 KO mice, lacking adaptive
immune NKT, T and B lymphocytes, but maintaining NK cell
innate immune functions. These results suggest that innate
NK-mediated antitumor immunity is not sufficient to inhibit
spontaneous metastasis, and adaptive immune lymphocytes are
the primary effector cells in our model. Next we addressed the role
Figure 6. Differences in tumor growth and metastasis between TM40D and TM40D-MB tumors in normal and immune deficient
mice. Orthotopic injection into the bilateral mammary fat pads of CD1d KO, Ja18 KO, RAG2 KO, or wildtype BALB/c mice, with either 1610
6 TM40D
(CD1d-hi) or TM40D-MB (CD1d-lo) cells, 5 mice per tumor group. Mice were monitored for tumor formation (tumor size of 0.3 cm), and mice in each
tumor group were euthanized at maximum allowable size (2 cm). (A) Comparison of TM40D (CD1d-hi) tumor growth in CD1d KO, Ja18 KO, RAG2 KO,
or wildtype BALB/c mice. (B) Differences in rates of tumor growth and metastasis between TM40D and TM40D-MB tumors in normal and immune
deficient mice. (C) Comparison of TM40D-MB (CD1d-lo) tumor growth in CD1d KO, Ja18 KO, RAG2 KO, or wildtype BALB/c mice. Data are mean 6 SD.
(D) Scatter plot depicting increased number of tumor foci counted per lung in TM40D or TM40D-MB tumor-implanted mice in immune-deficient
CD1d KO, Ja18 KO, RAG2 KO, or wildtype BALB/c mice. (* P#0.05, ** P,0.005, *** P#0.001, one-way ANOVA test). Data are representative of two
independent experiments.
doi:10.1371/journal.pone.0020702.g006
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compared to TM40D in wildtype, the rate of metastasis and
overall number of metastases per lung in TM40D-implanted
CD1d KO mice was significantly higher (P=0.0077). These
results demonstrate the importance of CD1d-restricted NKT cells
in regulating metastatic progression of CD1d-expressing tumors.
We predicted that TM40D tumors implanted in type I NKT-
deficient Ja18 KO mice would show similar rates of metastasis as
compared to CD1d KO mice, owing to the importance of type I
NKT cells in antitumor immunity. Surprisingly, we found a more
significant increase in the rate and frequency of lung metastases in
TM40D-implanted CD1d KO mice than in the Ja18 KO mice
(P=0.0164). These results establish the importance of adaptive
immunity and CD1d-restricted NKT cells in preventing metastatic
cancer progression of CD1d-expressing tumors, but do not directly
implicate the importance of type I NKT cells in this model.
In order to determine the importance of CD1d-restricted NKT
cells in regulating the immunity of tumors with downregulated
CD1d, TM40D-MB (CD1d-lo) tumors were also implanted in
wildtype, CD1d KO, Ja18 KO and RAG2 KO mice. In contrast
to TM40D tumor growth in these mice, growth of TM40D-MB
(CD1d-lo) cells varied dramatically between mouse groups
(Fig. 6C). Unlike the TM40D tumors that readily grew in CD1d
KO mice, TM40D-MB tumors did not grow at all in these mice
(Fig. 6B,C). These results were similar to those observed in CD1d-
deficient tumor models (15-12RM, CT26-L5), where CD1d KO
mice are highly resistant to tumor growth [37]. This suggests that
the presence of suppressive type II NKT cells in these tumors may
be more important in promoting tumor progression than the
absence of type I NKT cells. Accordingly, we would expect
TM40D-MB tumors to be able to grow and metastasize in Ja18
KO mice lacking only type I NKT cells. As predicted, TM40D-
MB tumors grew in Ja18 KO mice, although tumor growth rates
were on average slower than in wildtype mice (Fig. 6C).
Interestingly, in RAG2 KO mice deficient in all adaptive
lymphocytes, including NKT cells, TM40D-MB tumor growth
rates were significantly increased as compared to wildtype
(P=0.0127 at day 42 post tumor implantation), and similar to
the rate of TM40D in wildtype. These results are in line with
previous studies demonstrating increased rates of tumor growth in
RAG2 KO mice, owing to the importance of adaptive antitumor
immunity [56].
Next we assessed the ability of TM40D-MB (CD1d-lo) tumors
to metastasize to lung in these mice, as compared to TM40D
(CD1d-hi). While no tumor growth or metastasis was detected in
CD1d KO mice implanted with TM40D-MB, Ja18 KO mice
demonstrated a similar ability to metastasize to lung as compared
to wildtype, with increased number and size of lung tumor foci,
although this was not statistically significant (P=0.1877)
(Fig. 6B,D). Similar to TM40D, all of the RAG2 KO mice
implanted with TM40D-MB tumor cells readily metastasized to
lung, and the overall number of lung metastases for both groups
were significantly greater than in wildtype mice (P,0.001)
(Fig. 6B,D). These findings further implicate the role of adaptive
immune lymphocytes for preventing breast cancer metastasis in
our tumor model. The results of these experiments point to
potential differences in the ability of type I and type II NKT cells
to regulate antitumor immunity in CD1d-expressing vs. CD1d-
deficient tumors.
Discussion
The ability of CD1d-restricted iNKT cells to promote
antitumor immune responses has been documented in multiple
human and animal cancer studies [14,19,20]. Several tumor types
have been shown to express CD1d, and tumor expression of CD1d
has been directly correlated with the ability of iNKT cells to
induce direct tumor cytolysis in vitro and promote iNKT-mediated
tumor immunity in vivo [25,51]. To our knowledge, this is the first
study to address the role of CD1d expression and NKT-mediated
antitumor immunity in regulating breast cancer metastasis. In our
mouse model of breast cancer metastasis, we detected a significant
downregulation of CD1d in the highly metastatic TM40D-MB
cells, as compared to the low-metastatic TM40D cells. We
hypothesized that tumors may acquire a selective advantage by
downregulating expression of CD1d, thereby evading iNKT-
mediated immune surveillance and promoting metastatic cancer
progression.
The exact mechanisms of iNKT-mediated antitumor immunity
have yet to be fully elucidated, however iNKTs are known to have
both direct and indirect effector functions, including the ability to
activate both innate NK and adaptive T cell-mediated antitumor
immunity [22,23,24]. In our study, we show that downregulation
of CD1d in highly metastatic cells correlates with in vivo
suppression of iNKT-regulated immune effector cells, as evi-
denced by significantly decreased in vivo levels of iNKT, NK,
CD4
+ and CD8
+ T cells. The effect on iNKT immune suppression
was not attributed to differences in tumor burden, as all mice were
euthanized at the same tumor volume. In addition, while gene
knockdown of CD1d in TM40D cells had no effect on primary
tumor growth, mice implanted with these tumors demonstrated
significantly decreased splenic levels of iNKT and T effector cells
and a significant increase in spontaneous lung metastasis. These
results point to the importance of CD1d expression by tumor in
promoting iNKT-mediated antitumor immunity.
In addition to their indirect antitumor immune functions,
multiple studies confirm the ability of iNKTs to be directly
cytotoxic to tumor cells in a CD1d-dependent manner [24,25,26].
In this study, we demonstrated that enriched iNKT cells are
preferentially cytotoxic to breast cancer cells with increased CD1d
expression in vitro, and this effect could be partially abrogated by
the addition of anti-CD1d blocking antibody. Previous studies by
the Smyth group reported potent tumor inhibition by administer-
ing an anti-CD1d blocking antibody in mice bearing multiple
types of CD1d-deficient tumors, presumably by blocking the
suppressive functions of type II NKT cells [37,53,54]. As these
studies were conducted using CD1d-deficient tumors, it was
unknown whether similar effects could be achieved with CD1d-
expressing tumors. As demonstrated in our study, treatment of
mice bearing CD1d-expressing breast tumors in vivo with an anti-
CD1d blocking antibody did not inhibit tumor progression, but
instead significantly increased spontaneous lung metastasis. The
importance of CD1d expression by tumor was further validated by
shRNA knockdown of CD1d, which also demonstrated signifi-
cantly increased tumor metastasis to lung. These results highlight a
previously unrecognized role for tumor CD1d expression in
preventing spontaneous breast cancer metastasis, and provide
further evidence to support the direct cytotoxic effector role of
iNKT cells in antitumor immunity.
Previous studies in a MCA-induced fibrosarcoma model
reported only a minor contribution of direct iNKT antitumor
cytotoxicity in vivo [57]. In our study, we did not see direct
evidence of iNKT cytotoxicity in vivo as evidenced by the ability of
iNKT cells to affect tumor growth rate. Our highly metastatic
TM40D-MB (CD1d-lo) tumor cells actually grow slower than
TM40D (CD1d-hi) cells, both in vitro (unpublished data) and in vivo,
and modulation of tumor CD1d expression by either antibody
blockade or gene knockdown had no effect on primary tumor
NKT-Mediated Antitumor Immunity in Breast Cancer
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from the large number of transplanted tumor cells, where direct
iNKT effector functions may be quickly overwhelmed. Interest-
ingly, while very few iNKT cells remained in the tumor
microenvironment at the time of tumor harvest, the majority of
iNKT cells that remained were CD4
2/CD8
2 double negative
(DN) (data not shown), indicative of increased cytotoxic ability
[58]. Recent studies performed in the murine prostate TRAMP
model demonstrated that CD1d-positive TRAMP prostate tumor
cells could induce cytokine defects in tumor-infiltrating DN iNKT
cells [59]. CD1d-expressing cancer cells in the primary breast
tumor may provoke similar defects in iNKT function. Alterna-
tively, as TM40D tumor cells were able to metastasize to lung in a
CD1d-dependent manner, it is possible that the direct cytotoxic
functions of DN iNKT cells may be more important in targeting
circulating tumor cells, rather than decreasing primary tumor
burden. Further studies are required to more fully characterize the
direct vs. indirect cytotoxic functions of iNKT cells in preventing
spontaneous breast cancer metastasis.
In order to assess the relevance of these findings to human
breast cancer, we analyzed the expression of CD1d in several
human mammary cell lines of increasing metastatic potential by
RT-PCR. We provide the first evidence that expression of CD1d
in human mammary epithelial cells is lost in the transition from
normal to invasive breast cancer. However, not all metastatic cell
lines lost CD1d, as evidenced by the highly metastatic MDA-MB-
468 cells. Interestingly, these cells were originally acquired from an
African-American patient, while the equally metastatic MDA-MB-
231 cells were acquired from a Caucasian patient [60]. Differences
in genetic variation of CD1d haplotypes between these ethnicities
has been previously reported, and possible alternate slicing or
expression of CD1d between ethnicities is possible [61]. These
findings may have important clinical implications in tailoring
individual NKT-based immunotherapies for the treatment of
breast cancer. Treatment with an anti-CD1d blocking antibody
may be effective for CD1d-deficient tumors, however CD1d-
expressing tumors would likely be more responsive to iNKT-
activating therapies.
Studies in multiple murine tumor models have demonstrated
that type I (iNKT) and type II NKT cells have opposing regulatory
roles, with type I NKT cells demonstrating potent antitumor
immune responses, and type II NKT cells exhibiting mainly
immunosuppressive functions [14]. Type I NKT dominant
tumors, such as 4T1 mammary carcinoma and CT26 colon
carcinoma, have been shown to grow similarly in CD1d KO (type
I and II deficient) and Ja18 KO (type I deficient) mice as in
wildtype, but demonstrate increased metastasis in Ja18 KO mice
[37]. In these models, the presence of type I NKT cells is the
dominant factor in preventing metastasis, regardless of the
presence or absence of suppressive type II NKT cells. In contrast,
type II NKT dominant tumor models, such as subcutaneous 15-
12RM fibrosarcoma and CT26-L5 colon carcinoma, grow
normally in Ja18 KO mice but do not grow at all in CD1d KO
mice, highlighting the requirement of suppressive type II NKT
cells in promoting tumor progression of these cells. Importantly, all
of these tumor models are CD1d-deficient, and the role of CD1d-
expressing tumors in promoting a type I vs. type II NKT immune
response in non-hematopoietic tumors has not previously been
investigated. In a murine model of B cell lymphoma, CD1d-
expressing tumor cells demonstrated increased tumor progression
in Ja18 KO mice as compared to CD1d-deficient tumor cells [51].
This was suggested to be due to the ability of CD1d-expressing
tumor cells to recruit suppressive type II NKT cells in the absence
of type I NKT cells. Also in this model, CD1d KO mice were
highly resistant to tumor progression of both CD1d-expressing and
CD1d-deficient tumor cells, suggesting a dominance of suppressive
type II NKT cells.
In order to elucidate the specific roles of CD1d-restricted NKT
cells in our model of breast cancer, we utilized CD1d KO (type I
and type II NKT cell deficient), Ja18 KO (type I NKT cell
deficient) and RAG2 KO (B and T cell deficient) mice to compare
tumor growth and metastasis rates between our CD1d-lo and
CD1d-hi tumor cells. Our TM40D (CD1d-hi) tumors grew at the
same rate in all mouse strains, similar to the type I NKT dominant
4T1 mouse model [37]. However, while the CD1d-deficient 4T1-
implanted CD1d KO mice exhibited fewer metastases and
increased survival as compared to Ja18 KO mice, our CD1d-
expressing TM40D tumor cells showed the opposite effect, with
significantly increased metastasis in the CD1d KO mice as
compared to Ja18 KO mice. Similarly, while the Smyth group was
able to inhibit 4T1 metastatic growth by in vivo anti-CD1d
antibody blockade, our TM40D cells demonstrated significantly
increased metastasis upon in vivo antibody blockade. As antibody
blockade of CD1d-expressing tumors would similarly abrogate
direct type II NKT recruitment, our TM40D cells may not be able
to recruit type II NKT cells, as suggested in the B cell lymphoma
study [51]. Clearly, both tumor and systemic expression of CD1d
are important for preventing metastasis of TM40D tumors.
However, the specific contributions of type I and type II NKT
cells in regulating these tumors, as compared to other adaptive
immune cells, cannot be concluded at this time.
In order to directly assess the role of type I vs. type II NKT cells
in regulating CD1d-deficient tumors in our tumor model, we
implanted TM40D-MB (CD1d-lo) tumors in wildtype, CD1d KO,
Ja18 KO and RAG2KO mice. Similar to TM40D, TM40D-MB
tumors were highly metastatic in the RAG2 KO mice,
demonstrating the importance of adaptive lymphocytes in
regulating both TM40D and TM40D-MB tumors. As with other
type II NKT dominant CD1d-deficient tumor models, TM40D-
MB tumors did not grow at all in CD1d KO mice, yet were able to
grow and metastasize in type I NKT-deficient Ja18 KO mice.
These findings further demonstrate the importance of suppressive
type II NKT cells in promoting tumor progression of tumors with
downregulated CD1d.
Preliminary experiments in our lab with Ja18 KO mice
implanted with TM40D-MB tumors demonstrated a significant
increase in splenic CD49b
+ CD4
+ TCRb
+ cells, believed to be
type II NKT cells (unpublished results). This suggests that while
CD1d expression in these tumor cells is downregulated, they may
still be capable of being recognized by type II NKT cells. One
possible explanation for the discrepancy in recognition of TM40D
and TM40D-MB tumors by type II NKT cells is that it may not
depend solely on the expression level of CD1d. Rather, the ability
of CD1d-expressing tumor cells to promote type I over type II
NKT immune responses may depend more on the type of tumor
antigen presented by CD1d molecules. In support of this theory, a
recent study demonstrated that inflammation-associated lipids
presented by APCs in the tumor microenvironment preferentially
recruit suppressive type II NKT cells [62]. In addition, glycolipid
antigens recognized by type II NKT cells may differ from type I
NKT cells, in that type II NKT activation does not require CD1d
trafficking through endosomes [63,64]. As a tumor progresses, the
tumor microenvironment is well known to induce inflammation,
which facilitates tumor growth and eventually fosters the
recruitment of suppressive immune cells that further promote
metastatic tumor progression [65]. It may be that downregulation
of CD1d by the tumor is a fairly early event in tumor progression,
and thus not associated with the late-stage inflammatory tumor
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Thus, tumor downregulation of CD1d may be advantageous for
evasion of iNKT-mediated immune surveillance in the early stages
of tumor progression, when antigens presented by tumor cells such
as TM40D may preferentially elicit type I over type II NKT
antitumor immune responses. In late-stage metastatic breast
cancer, such as in TM40D-MB, presentation of inflammatory
tumor antigens by even a low level of CD1d may be sufficient to
drive type II NKT-mediated immune suppression. In our tumor
model, TM40D-MB tumors have been shown to be more
metastatic to lung and significantly more metastatic to bone than
TM40D tumors [8]. While the focus of this study was on early
spontaneous metastasis to lung, future studies characterizing the
ability of TM40D-MB cells in bone to preferentially recruit type II
NKT cells may shed light on mechanisms that increase their bone
metastatic potential.
In summary, the eradication of breast cancer through bolstering
iNKT-mediated antitumor immunity remains a promising thera-
peutic direction. The results of this study further support the
development of immunotherapeutics that increase the activation
and function of type I iNKT cells, while inhibiting the suppressive
effects of type II NKT cells. Based on our findings of the tumor-
promoting effects of anti-CD1d monoclonal antibody treatment of
CD1d-expressing tumor cells, current therapeutic strategies based
on globally inhibiting CD1d by antibody blockade are not
recommended. Rather, the CD1d expression status of the tumor
and the stage of disease progression may be important consider-
ations in tailoring future breast cancer immunotherapies that
effectively promote iNKT-mediated antitumor immunity.
Supporting Information
Figure S1 Downregulation of the gene encoding CD1d in
highly metastatic tumor cells identified by microarray.
Hierarchical cluster diagram of 86 genes (represented by 86 probe
sets) that were over- and under-expressed in cells highly metastatic
to bone (TM40D-MB) compared to TM40D cells. The Affymetrix
probe set number, fold differences, P-value and identities of the
genes are indicated. Data were analyzed by the Gene-Spring 5.0.3
array data analysis software (Silicon Genetics, Redwood City, CA)
and were normalized in the dChip software (Harvard School of
Public Health and Dana-Farber Cancer Institute, Boston, MA).
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